HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Accomplishes A-List Goals, Will Publish NDI Guidance – CFSAN

This article was originally published in The Tan Sheet

Executive Summary

FDA will publish guidance documents on new dietary ingredient submissions as part of an effort to update the industry on its premarket notification program, CFSAN announced in an Aug. 18 conference call on its program priorities

You may also be interested in...



Herbalife's Frankos Sees GMP Challenges In New Light After Leaving FDA

Vasilios "Bill" Frankos, former director of FDA's Division of Dietary Supplement Programs, left his mark on the industry after shepherding the supplement good manufacturing practices final rule from development to publication and through implementation

FDA Requiring GRAS-Level Safety Standards For NDI Submissions, Experts Say

FDA has gradually raised the safety standard for new dietary ingredients above the level intended by DSHEA, according to several experts

CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More

FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel